[go: up one dir, main page]

HRP20150007T8 - TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES - Google Patents

TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES

Info

Publication number
HRP20150007T8
HRP20150007T8 HRP20150007TT HRP20150007T HRP20150007T8 HR P20150007 T8 HRP20150007 T8 HR P20150007T8 HR P20150007T T HRP20150007T T HR P20150007TT HR P20150007 T HRP20150007 T HR P20150007T HR P20150007 T8 HRP20150007 T8 HR P20150007T8
Authority
HR
Croatia
Prior art keywords
antibodies
specific anti
tumor treatment
treatment assisted
assisted
Prior art date
Application number
HRP20150007TT
Other languages
Croatian (hr)
Inventor
Daniela Kelm
Peter Altevogt
Gerhard Moldenhauer
Frank Breitling
Achim Krüger
Silke Barreiter
Sandra Lüttgau
Ulrich Möbius
Yi Li
Susanne Sebens
Heiner Schäfer
Original Assignee
Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts, Medigene Ag filed Critical Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts
Publication of HRP20150007T1 publication Critical patent/HRP20150007T1/en
Publication of HRP20150007T8 publication Critical patent/HRP20150007T8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
HRP20150007TT 2007-06-15 2008-06-13 TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES HRP20150007T8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94435907P 2007-06-15 2007-06-15
EP08759230.9A EP2170956B1 (en) 2007-06-15 2008-06-13 Treatment of tumors using specific anti-l1 antibody
PCT/EP2008/004773 WO2008151819A2 (en) 2007-06-15 2008-06-13 Treatment of tumors using specific anti-l1 antibody

Publications (2)

Publication Number Publication Date
HRP20150007T1 HRP20150007T1 (en) 2015-03-13
HRP20150007T8 true HRP20150007T8 (en) 2015-08-14

Family

ID=39862994

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150007TT HRP20150007T8 (en) 2007-06-15 2008-06-13 TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES
HRP20180192TT HRP20180192T1 (en) 2007-06-15 2018-02-01 Treatment of tumors using specific anti-l1 antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20180192TT HRP20180192T1 (en) 2007-06-15 2018-02-01 Treatment of tumors using specific anti-l1 antibody

Country Status (16)

Country Link
US (3) US8138313B2 (en)
EP (2) EP2170956B1 (en)
JP (2) JP5921066B2 (en)
CA (2) CA2958672A1 (en)
CY (2) CY1115960T1 (en)
DK (2) DK2170956T3 (en)
ES (2) ES2658342T3 (en)
HR (2) HRP20150007T8 (en)
HU (1) HUE036490T2 (en)
LT (1) LT2631248T (en)
NO (1) NO2631248T3 (en)
PL (2) PL2631248T3 (en)
PT (2) PT2170956E (en)
SI (2) SI2170956T1 (en)
TW (1) TWI478939B (en)
WO (1) WO2008151819A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR20100060351A (en) * 2008-11-27 2010-06-07 한국생명공학연구원 A composition for treating l1cam-expressing cancer comprising an inhibitor of activity or expression of l1cam and anticancer agent
WO2012058627A2 (en) * 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
CN104936984B (en) 2012-11-16 2018-09-14 江原大学校产学协力团 Specifically bind the antibody and application thereof of people and mouse L1CAM
JP6875275B2 (en) * 2014-09-30 2021-05-19 ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ Binding molecules such as antibodies that bind to L1CAM (CD17)
WO2018026947A1 (en) 2016-08-02 2018-02-08 Memorial Sloan-Kettering Cancer Center Treating metastatic cancer and model systems for metastatic disease
WO2019111250A1 (en) 2017-12-05 2019-06-13 The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center T-cells comprising two different chimeric antigen receptors and uses thereof
CN113101364B (en) 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 Development and application of an autoimmune inhibitor
CN118754985A (en) 2018-06-29 2024-10-11 爱必泰生物有限公司 Anti-L1CAM antibodies and uses thereof
US20220298255A1 (en) * 2019-05-31 2022-09-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
JP2025532716A (en) 2022-09-21 2025-10-01 エルテラ アーゲー Novel binding molecule that binds to L1CAM
IL320220A (en) * 2022-11-09 2025-06-01 Cis Biopharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2025068389A2 (en) 2023-09-27 2025-04-03 Elthera Ag L1cam binding molecules for treating hematological malignancy diseases

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (en) * 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0469065T3 (en) 1989-04-21 1996-07-15 Protein Design Labs Inc Recombinant antibody toxin fusion protein
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
IE911922A1 (en) 1990-06-07 1991-12-18 Scripps Clinic Res Apo ai polypeptides, diagnostic methods and systems for¹quantifying apo ai, and therapeutic methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (en) * 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
ES2330052T3 (en) 1991-03-01 2009-12-03 Dyax Corporation CHEMICAL PROTEIN THAT INCLUDES MICRO-PROTEINS THAT HAVE TWO OR MORE DISULFURENT BRIDGES AND RELATIONSHIPS OF THE SAME.
ATE414768T1 (en) 1991-04-10 2008-12-15 Scripps Research Inst LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS
DE69233254T2 (en) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP0626012B1 (en) * 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
AU4953693A (en) 1992-08-25 1994-03-15 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
DE19819846B4 (en) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CN1320044A (en) * 1998-08-11 2001-10-31 Idec药物公司 B-Cell Lymphoma Combination Therapy Including Administration of Anti-CD20 Antibody
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1172654B1 (en) 2000-07-10 2007-10-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors
DE60124912T2 (en) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimeric, single chain, tandem Fv antibodies
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
KR100470535B1 (en) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 Immunoliposome conjugated with upa antibody
WO2004037198A2 (en) 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Antibody-mediated induction of tumor cell death
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
GB0306618D0 (en) 2003-03-22 2003-04-30 Univ Newcastle Antibody
EP1623995A1 (en) 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
JP2009506790A (en) 2005-09-07 2009-02-19 メディミューン，エルエルシー EPH receptor antibody conjugated to toxin
WO2007114550A1 (en) * 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
CA2661665A1 (en) 2006-08-23 2008-02-28 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating lung cancer, a method for inhibiting growth or invasion of lung cancer and a method for treating lung cancer
AU2007221863A1 (en) 2006-10-16 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offenftlichen Rechts Treatment of chemotherapy -or radiothereapy-resistant tumors

Also Published As

Publication number Publication date
PL2170956T3 (en) 2015-04-30
JP2010529970A (en) 2010-09-02
HUE036490T2 (en) 2018-07-30
US9260521B2 (en) 2016-02-16
SI2170956T1 (en) 2015-02-27
CA2958672A1 (en) 2008-12-18
CY1115960T1 (en) 2017-01-25
LT2631248T (en) 2018-04-25
DK2170956T3 (en) 2015-02-02
JP5921066B2 (en) 2016-05-24
WO2008151819A3 (en) 2009-04-09
DK2631248T3 (en) 2018-02-12
CA2691075C (en) 2017-04-11
EP2170956A2 (en) 2010-04-07
CY1119890T1 (en) 2018-06-27
ES2658342T3 (en) 2018-03-09
NO2631248T3 (en) 2018-04-14
US8580258B2 (en) 2013-11-12
EP2631248B9 (en) 2018-05-23
EP2631248A2 (en) 2013-08-28
TW200918556A (en) 2009-05-01
ES2658342T9 (en) 2018-06-06
EP2631248A3 (en) 2013-10-23
CA2691075A1 (en) 2008-12-18
US20140120117A1 (en) 2014-05-01
EP2170956B1 (en) 2014-10-22
US20090162355A1 (en) 2009-06-25
PT2631248T (en) 2018-02-15
HRP20150007T1 (en) 2015-03-13
TWI478939B (en) 2015-04-01
ES2528167T3 (en) 2015-02-04
PT2170956E (en) 2015-02-05
SI2631248T1 (en) 2018-04-30
PL2631248T3 (en) 2018-06-29
WO2008151819A2 (en) 2008-12-18
EP2631248B1 (en) 2017-11-15
US8138313B2 (en) 2012-03-20
US20120258039A1 (en) 2012-10-11
HRP20180192T1 (en) 2018-04-06
JP6042395B2 (en) 2016-12-14
JP2015042651A (en) 2015-03-05

Similar Documents

Publication Publication Date Title
HRP20150007T8 (en) TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES
BR112012004546A2 (en) "dll4-ligand protein therapy"
HRP20180572T1 (en) 1 '-SUBSTITUTED CARBA-NUCLEOSIDE ANALYSIS FOR ANTI-VIRUS THERAPY
IL197217B (en) New antibodies against 38cd for cancer treatment
BRPI0810206A2 (en) CANCER TREATMENT METHOD
IL233023A (en) Methods for characterizing cancer in a patient
PT2426148E (en) ANTI-RÁ-IL-3 ANTIBODY FOR USE IN THE TREATMENT OF BLOOD TUMORS
BRPI0906389A2 (en) Skin therapy system
IT1391555B1 (en) EXTRACORPOREO BLOOD TREATMENT SYSTEM
HUE036477T2 (en) Monoclonal anti-GT468 antibodies to treat cancer
DE602008005894D1 (en) CONDENSED IMIDAZOLE FOR CANCER TREATMENT
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
SI2126093T1 (en) Improving protein preparation
BRPI0910854A2 (en) treatment methods
PT2242773T (en) Monoclonal antibodies for tumor treatment
BRPI0908026A2 (en) Methods for the treatment of bowel diseases
LTPA2016041I1 (en) Treatment Methods Using Drugs - Ammonia Traps
HRP20150449T1 (en) METHODS OF TREATMENT OF MULTIPLOG MYELOMA USING COMBINED THERAPY BASED ON ANTI-CS1 ANTIBODIES
HRP20160764T1 (en) PAPILOMAVIRUS PSEUDOVIRUSES FOR TUMOR DETECTION AND TREATMENT
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
BRPI0815551A2 (en) TREATMENT THROUGH HUCBC OF BETA-AMYLOID DISEASE
BRPI0909016A2 (en) antibodies useful for cancer treatment
EP2432539A4 (en) HYPERTHERMIA ASSISTED RADIOTHERAPY
BRPI0813364A2 (en) DIAGNOSTIC METHODS AND CANCER TREATMENT.
HRP20180485T1 (en) GT468 MONOCLONAL ANTIBODIES FOR CANCER TREATMENT